Resistance prevalence profile of *Klebsiella pneumoniae* in the Intensive Care Units of Al-Shatby Pediatric Hospital, Alexandria, Egypt

Bassma H. Elwakil; Safaa M. Ali; Soad F. Hafez; Adnan A. Bekhit; Moustafa Y. El-Naggar; Zakia A. Olama

1Department of Medical Laboratory Technology, Faculty of Allied Medical Science, Pharos University in Alexandria, Egypt; 2Department of Nucleic acid research, GEBRI, City for Scientific Research and Technology applications, Alexandria, Egypt; 3Department of Microbiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt; 4Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Egypt; 5Department of Botany and Microbiology, Faculty of Science, Alexandria University, Egypt

*Corresponding author E-mail: safaa.mohamedali@yahoo.com, sali@srtacity.sci.eg*

Received: 16 November, 2019; Accepted: 18 December, 2019; Published online: 28 December, 2019

**Abstract**

*Klebsiella pneumoniae* has been identified as an opportunistic pathogen associated with both community-acquired and nosocomial infections mainly among patients admitted to the Intensive care units (ICUs). Some resistant genes were transferred vertically or horizontally within many microbial communities, directly between bacteria through plasmids or integrin. Different techniques including; phenotypic and genetic ones were used to evaluate the presence of β-lactamases among the isolated strains of *K. pneumoniae*. This bacterial species is the most commonly isolated pathogen (95 isolates) from all the examined samples (51.35%). Current results revealed that 30 and 14 strains of *K. pneumoniae* are positive to Extended spectrum β-lactamase (ESBL) production, and AmpC β-lactamase producers, respectively. On the other hand, modified carbapenem inactivation and modified Hodge test (MHT) were used to assess the carbapenem resistant strains. It is observed that all the β-lactamase producers’ strains are also carbapenemase producers, whereas only nine strains (30%) are MHT positive. The Polymerase Chain Reaction (PCR) technique revealed that TEM, BETA, NDM and IPM genes are found on the bacterial plasmid (100%). However the presence of the β-lactamase genes on the bacterial DNA varied among the different strains. The presence of the resistance genes on the bacterial plasmid may signify the resistance acquired upon the previous exposure of this bacterium to the different antibiotics. The aims of the current work were to isolate *K. pneumonia* from Al-Shatby hospital ICUs, to determine the incidence of its β-lactamases, and to decide the frequency of acquisition of 12 different genes among ESBL *K. pneumoniae* isolates.

**Keywords:** *Klebsiella pneumoniae*; Multi-drug resistance; β-lactamases; Gene
1. Introduction

During the past decades, the emerging problem of ESBL producing bacteria has received a great attention. Doi et al., (2013) reported that the most commonly important ways by which the Gram-negative bacteria can resist β-lactam antibiotics are through the production of enzymes (β-lactamase enzymes) capable of hydrolyzing the β-lactam ring of the antibiotics.

According to Falagas et al., (2014), *K. pneumoniae* carbapenemase (KPC) enzyme is the most commonly encountered enzyme among these isolates. Lutgring and Limbago, (2016) study revealed that the mechanisms of carbapenem resistance in the family Enterobacteriaceae are multifarious. They consist of β-lactamases carbapenem hydrolyzing enzymes construction, and resistance in line for the combination of other factors including ESBLs or AmpC β-lactamases hyper-production. The Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) can spread rapidly, and their detection may warrant implementation of more-intensive infection control interventions than would be employed for none-CP-CRE (CDC. 2013). In addition, Tamma et al., (2016) reported that CP-CRE has more hazardous influence than none-CP-CRE. The Gram-negative β-lactamases are regulated by several genes such as: blaCTX-M, blaTEM and blaSHV (Monstein et al., 2007).

The Ambler's molecular classification is based on the nucleotide and amino acid sequences of the β-lactamases enzymes. Four classes (A, B, C and D) are documented as conforming to Ambler's classification. The classes (A, C and D) have serine deposit, while the class B has cysteine or histidine residue singly or together (Ambler, 1980; Papp-Wallace et al., 2018). This study aimed to evaluate the incidences of the resistant MDR, ESBL, and CRKP genes of the *K. pneumoniae* isolates recovered from the ICUs of Al-Shatby Pediatric Hospital, Alexandria, Egypt.

2. Materials and methods

2.1. Sampling and collection of the bacterial isolates

This prospective cohort study was conducted over 7 months from the 1st of January to the 31th of July, 2017, at the Surgical sites ICU, Neonates ICU “NICU”, and Pediatric ICU “PICU”, of Al-Shatby Pediatric Hospital. The different clinical samples were collected from the mid-stream urine, blood, and from the broncho-alveolar lavage (BAL).

All the bacterial isolates used throughout this work were kindly provided and phenotypically identified by the Surveillance Microbiology Department Strain Bank, at Al-Shatby Pediatric Hospital, Alexandria, Egypt. The strains of *Klebsiella* ATCC 13883, *Klebsiella* 1705 (ESBL +ve), *Klebsiella* 1706 (ESBL -ve), and *Escherichia coli* ATCC 25922, were kindly provided by the Naval Medical Research Unit (NAMRU) no.3, Cairo, Egypt.

2.2. Identification of the bacterial isolates

The morphological features of each bacterial isolate was studied (Noor et al., 2014), and then identified biochemically (Barrow and Feltham, 1993). Additional identification for the selected *Klebsiella* isolates was carried out using Thermo Fisher Scientific RapIDTM ONE System (REF: R8311006); which was an identification system based on enzyme technology, and Vitek 2 automated system (bioMerieux, Marcy l’Etoile, France), at the Medical Research Center (MRC), Faculty of Medicine, Alexandria University, Alexandria, Egypt.

2.3. Evaluation of the prevalence of resistance among the *K. pneumoniae* strains

The disc-diffusion assay (Bauer et al., 1959) was evaluated using different groups of common antibiotics including: aminopenicillins, 1st generation cephalosporins, aminoglycosides (tobramycin), ureidopenicillins, trimethoprim-sulfamethoxazole, and monobactams, and then incubated at 35± 2°C for 24 h.
2.4. Detection of the Extended-spectrum β-lactamase in *K. pneumoniae*

The Double-disc synergy test (DDST) (Jaspal et al., 2013) and the CLSI confirmatory test [Recommends a phenotypic confirmatory combined-disk test for ESBL production in Enterobacteriaceae. It consists of measuring the growth-inhibitory zones around both cefotaxime (CTX) and ceftazidime (CAZ) disks with or without clavulanate (CA)] (Aggeliki et al., 2014), were used for detection of the ESBL. The DDST was carried out using Cephalosporins discs which were placed in the petri plates next to a centrally placed disc of clavulanic acid (amoxicillin/ clavulanic acid 20/ 10 μg), according to CLSI. (2015). AmpC β-lactamases were clinically important cephalosporinases and Cefoxitin (Jacoby, 2009).

2.5. Phenotypic carbapenamase assembly recognition of *K. pneumoniae*

The Modified Hodge test (MHT) (Saito et al., 2015), and the Reformed Carbapenem Inactivation Method (CLSI, 2017; Bayraktar et al., 2018) were carried out in the selected bacterial isolates.

2.6. Determination of the *K. pneumoniae* resistance genes using molecular techniques

The DNA of the selected *K. pneumoniae* isolates was extracted using Thermo Scientific GeneJET Genomic DNA Purification Kit, while the plasmids of these isolates were extracted using GEBRI kit. To detect the presence of β-lactamases genes, normalization of the DNA and the plasmid concentrations were performed to avoid the dissimilarities between both concentrations before use. About twelve primers were designed (Table 1) and the genes used to mark the β-lactamase class A were; TEM, CTX, KPC, Beta and SHV. The β-lactamase Class B (carbapenemase encoding) genes were; VIM, IMP and NDM, whereas the β-lactamase class C encoding gene was FOX. Finally, the β-lactamase class D encoding genes were OXA-10, OXA-24 and OXA-58 (Pérez-Pérez and Hanson, 2002; Mariana et al., 2004).

3. Results

3.1. Sample collection and identification of the bacterial isolates

A total of 1470 samples were collected from 949 ICU hospitalized patients that were distributed as follows: Surgical, PICU and NICU (11.59, 15.91 and 72.49%, respectively) of the patients admitted. A total of 1217 out of 1470 samples are considered sterile, whereas 68 samples are considered as contaminated samples. The most commonly isolated pathogen from all the examined samples is *Klebsiella* sp. representing 51.35% (95 out of the total 185 isolated pathogens), and is distributed as 5.27, 25.26 and 69.47% in urine, BAL and blood samples, respectively. The Vitek 2 and RapID™ one systems were used for identification of *Klebsiella* sp., and they confirmed their identification as *K. pneumoniae* with > 99.9% confidence level. Results in Table (2) revealed that the incidence of Gram-negative bacterial isolates detected in the ICUs’ is 69.18%, while it is 18.91% for Gram-positive bacteria. The incidence of the isolated bacterial spp. revealed that *Klebsiella* sp. is the most commonly isolated pathogen followed by *Candida albicans*, Coagulase negative Staphylococcus (CONS), and *Pseudomonas aeruginosa* with; 51.35, 11.89, 7.57 and 6.49%, respectively.

3.2. Evaluation of prevalence of resistance among the *K. pneumoniae* strains

The prevalence of antibiotics resistance among the isolated strains of *K. pneumoniae* revealed that they are resistant to aminopenicillins, 1st generation cephalosporins, aminoglycosides (tobramycin), ureidopenicillins, trimethoprim-sulfamethoxazole, and monobactams. The *K. pneumonia* strains exhibited high resistance pattern to colistin and meropenem antibiotics (81 and 55.7%, respectively), as clear in Table (3), Fig. (1). These results may represent a high risk and provide very limited options for treatment of bacterial infections. However, it may raise an alert for a surveillance program to monitor the bacterial trends and antibiotics resistance patterns in Egypt.
Table 1. Primers sequences used for screening of genes encoding β-lactamases classes A-D

| Class | Primer | Sequence | Product size (bp) |
|-------|--------|----------|------------------|
| Class A | CTX | F: ATGTGCAGYACCAGTAARGTKATGCC | 550 |
| | Beta | F:ATAAAAGCGGTCTGCTGTITTT | 686 |
| | KPC | F: GCTTTC(T/G)GCTGTCG/A/CAGTCGTCG/C/ACGC | 412 |
| | SHV | F: GTATAATTACCTC/T/CTGTCGAC/A/GC| 868 |
| | TEM | F: TCCTGCTGGTATGCGGCAGGAAAG | 1100 |
| Class B | VIM | F: GATGGTGTTTGGTCGCATATCGCAAC | 500 |
| | IPM | F: AG/GAGCG/GTCGAATAGTGGC/CTTCAG/CTC/T/A/GCACAACAYACTAGTATC | 432 |
| | NDM | F: CAAAGTGCGCTGTCGCAGCAGCAGGTG | 475 |
| Class C | FOX | F: AACATGGGGTATCAGGGAGATG | 190 |
| Class D | OXA-10 | F: ATGGTCTCTGCTGCTTT | 564 |
| | OXA-24 | F: GTACTATCAAAATGTGGAA | 246 |
| | OXA-58 | F: CCCCTC/TGTGCTTCATACATAACATC | 599 |

Table 2. Distribution of the bacterial isolates recovered from the different clinical samples

| Name of the bacterial isolates | Number of isolates (%) | Number and percentage (%) of the isolation sources |
|--------------------------------|------------------------|--------------------------------------------------|
|                                |                        | Blood    | Urine    | BAL      |
| **C. albicans**                | 22.0 (11.89)           | 7.0 (3.78)| 10.0 (5.40)| 5.0 (2.70)|
| Acinetobacter sp.              | 9.0 (4.86)             | 4.0 (2.16)| 0.0 (0)   | 5.0 (2.70)|
| Citrobacter sp.                | 1.0 (0.54)             | 1.0 (0.54)| 0.0 (0)   | 0.0 (0)   |
| E. coli                       | 10.0 (5.40)            | 7.0 (3.78)| 2.0 (1.08)| 1.0 (0.54)|
| K. pneumonia                   | 95.0 (51.35)           | 66.0 (35.68)| 5.0 (2.3)  | 24.0 (12.97)|
| P. aeruginosa                  | 12.0 (6.49)            | 0.0 (0)   | 3.0 (1.4) | 9.0 (4.68) |
| Stenotrophomonas sp.           | 1.0 (0.54)             | 1.0 (0.54)| 0.0 (0)   | 0.0 (0)   |
| **Total Gram-negative**        | 128.0 (69.18)          | 79.0 (42.70)| 10.0 (5.40)| 39.0 (21.08)|
| **CONS**                       | 14.0 (7.57)            | 10.0 (5.40)| 0.0 (0)   | 4.0 (2.16)|
| E. faecalis                    | 10.0 (5.40)            | 6.0 (3.24)| 4.0 (2.16)| 0.0 (0)   |
| MRSA                           | 7.0 (3.78)             | 6.0 (3.24)| 0.0 (0)   | 1.0 (0.54)|
| S. aureus                      | 1.0 (0.54)             | 1.0 (0.54)| 0.0 (0)   | 0.0 (0)   |
| S. pneumoniae                  | 1.0 (0.54)             | 0.0 (0)   | 0.0 (0)   | 1.0 (0.54)|
| S. viridans                    | 2.0 (1.08)             | 1.0 (0.54)| 0.0 (0)   | 1.0 (0.54)|
| **Total Gram-positive**        | 35.0 (18.91)           | 24.0 (12.97)| 4.0 (2.16)| 7.0 (3.78)|
| **Total**                      | 185.0                  | 110.0 (59.46)| 24.0 (12.97)| 51.0 (27.57)|

-Results are averages of three replicates. Where; CONS: Coagulase negative *Staphylococcus*, MRSA: Multi drug resistant *Staphylococcus aureus*, BAL: Broncho-alveolar lavage
Table 3. Antibiogram of all the isolated *K. pneumoniae* strains

| Antibiotic group | Antibiotic                          | Number and resistance percentage (%) |
|------------------|-------------------------------------|--------------------------------------|
|                  |                                     | Sensitive strains | Intermediately sensitive strains | Resistant strains | R* | S* |
| Aminopenicillins | Ampicillin                          | 0.0 (0)            | 0.0 (0)                          | 95.0 (100)        | <13 | >17 |
| 1st generation cephalosporins | Cefazolin                          | 0.0 (0)            | 0.0 (0)                          | 95.0 (100)        | <19 | >23 |
| Aminoglycosides  | Tobramycin                          | 0.0 (0)            | 0.0 (0)                          | 95.0 (100)        | <12 | >15 |
|                  | Amikacin                            | 21.0 (22.1)        | 27.0 (28.4)                      | 47.0 (49.4)       | <14 | >17 |
| Ureidopenicillins | Pipracillin                         | 0.0 (0)            | 0.0 (0)                          | 95.0 (100)        | <17 | >21 |
| β-lactams-β-lactamase inhibitor | Amoxicillin/ Clavulanate         | 3.0 (3.1)          | 18.0 (18.9)                      | 74.0 (77.8)       | <13 | >18 |
|                  | Ampicillin/ Sulbactam                | 0.0 (0)            | 6.0 (6.3)                        | 89.0 (93.6)       | >12 | >15 |
|                  | Pipracillin/ Tazobactam              | 9.0 (9.4)          | 9.0 (9.4)                        | 77.0 (81)         | <17 | >21 |
|                  | Cefoperazone/ Sulbactam              | 0.0 (0)            | 15.0 (15.7)                      | 80.0 (84.2)       | <15 | >21 |
| 2nd generation cephalosporins | Cefoxitin                           | 39.0 (41)          | 9.0 (9.4)                        | 47.0 (49.4)       | <14 | >18 |
| 3rd generation cephalosporins | Cefotaxime                          | 0.0 (0)            | 6.0 (6.3)                        | 89.0 (93.6)       | <14 | >23 |
|                  | Cefoperazone                         | 0.0 (0)            | 3.0 (3.1)                        | 92.0 (96.8)       | <15 | >21 |
|                  | Ceftriaxone                          | 0.0 (0)            | 6.0 (6.3)                        | 89.0 (93.6)       | <19 | >23 |
| Carbapenems      | Meropenem                           | 21.0 (22.1)        | 21.0 (22.1)                      | 53.0 (55.7)       | <19 | >23 |
| Quinolones       | Ciprofloxacin                       | 3.0 (3.1)          | 9.0 (9.4)                        | 83.0 (87.3)       | <20 | >31 |
|                  | Trimethoprim-Sulfamethoxazole       | 0.0 (0)            | 15.0 (15.7)                      | 80.0 (84.2)       | <10 | >16 |
| Monobactams      | Aztreonam                           | 0.0 (0)            | 0.0 (0)                          | 95.0 (100)        | <17 | >21 |
| Phenicols        | Cholramphenicol                     | 51.0 (53.6)        | 18.0 (18.9)                      | 26.0 (27.3)       | <12 | >18 |
| Tetracyclines    | Doxycycline                         | 6.0 (6.3)          | 9.0 (9.4)                        | 80.0 (84.2)       | <10 | >14 |
| Polymyxins       | Colistin                            | 9.0 (9.4)          | 9.0 (9.4)                        | 77.0 (81)         | <11 | >14 |

Results are averages of three replicates. Where; * According to CLSI. (2015), R: Resistant, S: Sensitive, NRS: Number of Resistant Strains, NIS: Number of Intermediate Strains, NSS: Number of Sensitive Strains, %: Percentage of strain resistance to each listed antibiotic

Fig. 1. Sensitivity of *E. coli* ATCC 25955 (a) and *K. pneumoniae* strains (b) to meropenem antibiotic
3.3. Detection of the Extended-Spectrum β-lactamase in *K. pneumonia* using (DDST) and CLSI confirmatory assays

In a trial to recognize the ESBL producing *K. pneumonia* strains, the double disc synergy (DDST) and CLSI examinations were used. Results in Fig. (2 a, b) demonstrated that 27 and 30 out of the 95 of isolated *K. pneumoniae* strains are ESBL producers using the DDST, while the CLSI confirmatory assays presenting; 28.4 and 31.5%, respectively.

3.4. Screening for the AmpC β-lactamase production

In the current study, 14 out of 30 (46.6%) of ESBL positive *K. pneumoniae* strains are considered as AmpC β-lactamase producing bacteria as shown in Fig. (2c).

3.5. Phenotypic detection of carbapenemases production by *K. pneumoniae*

In a trial to detect carbapenemase production by the bacteria under investigation, a confirmatory test known as Modified Carbapenem Inactivation Method (mCIM) (Virginia *et al.*, 2017) was evaluated. Results presented in Fig. (3) revealed that all the 30 strains of the tested bacteria are Extended spectrum β-lactamase (ESBL) positive, and are carbapenemase producers. About 9 out of the 30 ESBL *K. pneumoniae* strains are proved to be carbapenem-resistant *Klebsiella pneumoniae* (CRKP) positive. The MHT is considered positive, because the *E. coli* 25922 strain showed a clover leaf-like indentation along with *K. pneumoniae* growth within the meropenem diffusion inhibition zone.

![Fig. 2. Detection of ESBL *Klebsiella pneumoniae* using DDST (a), CLSI confirmatory test (b), and AmpC β-lactamase (c)](image)

![Fig. 3. Detection of carbapenemase production by *K. pneumoniae* strains (K1, K5, K7 and K15) using the Modified Hodge test (MHT)](image)
3.6. Screening for the β-lactamase genes in the *K. pneumoniae* strains using PCR

The PCR technique was used to amplify the genes of the 9 selected *K. pneumoniae* strains, where strain 1-9 proved to be Multi drug resistant (MDR), ESBL and CRKP, and were compared to the reference strains (ESBL +ve 1705, ESBL -ve 1706, and bacteria with ATCC 13883) (Fig. 4-7). It is interesting to note that the TEM and BETA genes are detected on the plasmid in all the 9 tested strains of *K. pneumoniae*. However, the percentage of their presence on the DNA varied among the *K. pneumoniae* strains (TEM and BETA, 44.44 and 33.33%, respectively). Results revealed that NDM and IPM genes are present (100%) on the plasmid in all the tested *K. pneumoniae* strains. However, their percentages are variable i.e. VIM and NDM are present in 11.11 and 66.66% on the DNA, respectively. The presence of the FOX gene on the DNA and the plasmid of all tested strains are variable (11.11 and 55.55%, respectively). The OXA-10 and OXA-24 genes are variably detected on the plasmid (22.22 and 11.11%, respectively). The current results demonstrated that the ICU's patients harbored most of the carbapenem-resistant strains, with the highest percentage of carbapenemases resistance genes are detected in *K. pneumoniae*.

**Fig. 4.** Agarose gel electrophoresis showing: PCR detection of TEM on DNA (A) and plasmid (B), KPC on DNA (C) and plasmid (D), SHV on DNA (E) and plasmid (F), BETA on DNA (G) and plasmid (H)

**Fig. 5.** Agarose gel electrophoresis showing: PCR detection for VIM on DNA (A) and plasmid (B), NDM on DNA (C) and plasmid (D), IPM on DNA (E) and plasmid (F)
Fig. 6. Agarose gel electrophoresis showing: PCR detection of FOX gene on DNA (A) and plasmid (B).

Fig. 7. Agarose gel electrophoresis showing: PCR detection of OXA-10 gene on DNA (A) and plasmid (B), OXA-24 on DNA (C) and plasmid (D).

4. Discussion

Recently, Labib et al. (2018) reported that 291 isolates of Gram-negative bacteria out of 1420 patients admitted to the PICU with a mortality rate of 37.1% were detected in 2 PICUs at the Cairo University Hospitals, Egypt. However, Klebsiella sp. (36.0%) was the most frequently isolated microorganism. Similarly, Amer et al. (2017) detected the distribution of carbapenem resistance in a survey study within the different patient's samples (BAL, blood, CVP and skin and soft tissues). The recorded percentage of carbapenem resistance distribution in the K. pneumoniae strains was 39%. Previously, Ejaz, (2013) illustrated that in a total number of 710 K. pneumoniae; only 214 (30.1%) were ESBL positive, while Saied et al., (2011) revealed that ESBL was detected in 79% of the K. pneumonia, and 39% of E. coli using the DDST test.

In a comparative study for detection of the accuracy between DDST and CLSI confirmatory tests, Amin et al., (2013) reported that 25 (75.75%) out of 33 isolates were identified by the DDST, whereas, 33 (100%) were identified using the CLSI confirmatory assay. Gupta et al., (2014) reported that AmpC β-lactamase detection may be difficult. In the study of Amjad et al., (2011), 138 isolates out of 200 were carbapenemase positive detected by using Modified Hodge test, and were distributed as follows: E. coli (38%), P. aeruginosa (30%), K. pneumoniae (17%).

The TEM-type gene has an average Mw of 1100 bp, while SHV-gene has 868 bp as reported by Polse et al., (2016). However, Trung et al., (2015) reported that KPC gene has an average Mw of 412 bp, while the BETA gene (686) detection was done by using a specific primer designed according to Klebsiella sp. information documented in the GenBank. On the other hand, the VIM-, NDM- and IMP-type genes have an average Mw of 500, 475 and 432 bp; respectively, which were similar to the findings of Shanthi et al., (2014). The FOX-type gene has an average Mw of 190 bp, which was similar to the molecular weight recorded by Sorour et al., (2008). Similar to the current findings, Najar et al., (2013) reported that OXA-24 and OXA-58 genes have average Mw of 564 and 246 bp, respectively.

Conclusion

The current results of incidences of the ESBL and CRKP of K. pneumoniae in the ICU’s at Al-Shatby Pediatric Hospital, Alexandria, Egypt, may pave the way for a surveillance program to monitor the resistance patterns of this pathogenic bacterium, thus
provide a clear vision towards the correct treatment options.

Acknowledgement

The authors would like to thank Mr. Ahmed Elkhwas for his great efforts in helping and supporting us in the lab, and solving all technical problems.

Conflict of interest

No conflict of interests exists between the authors of this study.

5. References

Aggeliki, P.; Evgenia, G.; Georgia, V.; Vassiliki, K.; Theodoros, P.; Spyros, P. and Athanassios, T. (2014). Modified CLSI Extended-Spectrum B-Lactamase (ESBL) Confirmatory Test for Phenotypic Detection of ESBLs among Enterobacteriaceae Producing Various -Lactamases. Journal of Clinical Microbiology. 4: 1483–1489.

Ambler, R.P. (1980). The structure of β-lactamases. Phil. Trans. R. Soc. Lond. B, 289(1036): 321-331.

Amer, W.H.; Elrifaey, S.M. and El Sharaby, R.M. (2017). Blood stream infections in children with malignance: a single center experiences risk factors, microbiological isolates and sensitivity pattern. Microbiology Research Journal International. 18: 1-12.

Amin, H.; Zafar, A.; Ejaz, H. and Jameel, N.U.A. (2013). Phenotypic characterization of ESBL producing Enterobacter cloacae among children. Pakistan Journal of Medical Sciences. 29(1):144.

Amjad, A.; Mirza, I.A.; Abbasi, S.A.; Farwa, U.; Malik, N. and Zia, F. (2011). Modified Hodge test: A simple and effective test for detection of carbapenemase production. Iranian Journal of Microbiology. 3(4):189.

Barrow, G.I. and Feltham, R.K.A. (1993). Cowan and Steel’s manual for the identification of medical bacteria. 3. ed. Cambridge: Cambridge University Press, 1993. 216

Bauer, A.W.; Perry, D.M. and Kirby, W.M.M. (1959). Single disc antibiotic sensitivity testing of Staphylococci. AM.A Arch. Intern. Med. 104: 208-216.

Bayraktar, B.; Barış, A.; Malkoçoğlu, G.; Erdemir, D. and Kına, N. (2018). Comparison of Carba NP-Direct, Carbapenem Inactivation Method, and β-CARBA Tests for Detection of Carbapenemase Production in Enterobacteriaceae. Microbial Drug Resistance. 25(1): 97-102.

CDC. (2013). Healthcare-associated Infections (HAIs). The Burden. Available at: http://www.cdc.gov/HAI/burden.html.

CLSI. (2017). Performance standards for antimicrobial susceptibility testing. CLSI document M100-S26. Wayne, PA: Clinical and Laboratory Standards Institute.

CLSI. (2015). Performance standards for antimicrobial susceptibility testing; twenty fifth informational supplements. 35(3) CLSI document M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute.

Doi, A.; Shimada, T.; Harada, S.; Iwata, K. and Kamiya, T. (2013). The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. International Journal of Infectious Diseases. 17(3): 159-163.

Ejaz, H. (2013). Detection of extended-spectrum β-lactamases in Klebsiella pneumoniae: Comparison of phenotypic characterization methods. Pakistan Journal of Medical Sciences. 29(3): 768.

Falagas, M.E.; Tansarli, G.S.; Karageorgopoulos, D.E. and Vardakas, K.Z. (2014). Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerging Infectious Diseases. 20(7): 1170.
Gupta, G.; Tak, V. and Mathur, P. (2014). Detection of AmpC β-lactamases in Gram-negative bacteria. Journal of Laboratory Physicians. 6(1): 1.

Jacoby, G.A. (2009). AmpC β-lactamases. Clinical Microbiology Reviews. 22(1):161-182.

Jaspal, K.; Shashi, C. and Sheevani, G.M. (2013). Modified Double Disc Synergy Test to Detect ESBL Production in Urinary Isolates of Escherichia coli and Klebsiella pneumoniae. Journal of Clinical Diagnostic Research. 7(2): 229–233.

Labib, J.R; Ibrahim, S.K.; Salem, M.R.; Youssef, M.R.L. and Meligy, B. (2018). Infection with Gram-negative bacteria among children in a tertiary pediatric hospital in Egypt. American Journal of Infection Control. 46(7): 798-801.

Lutgring, J.D. and Limbago, B.M. (2016). The problem of carbapenemase producing carbapenem-resistant Enterobacteriaceae detection. Journal of Clinical Microbiology. 54: 529-534.

Mariana, C.; Mark, A.T.; Ronald, N.J.; Franz, J.S. and Timothy, R.W. (2004). Molecular Characterization of aB-Lactamase Gene, blaGIM-1, Encoding a New Subclass of Metallo β-lactamase. American Society for Microbiology. 48(12): 4654-4661.

Monstein, H.J.; Östholm-Balkhed, Å.; Nilsson, M.V.; Nilsson, M.; Dornbusch, K. and Nilsson, L.E. (2007). Multiplex PCR amplification assay for the detection of blaSHV, blaTEM and blaCTX-M genes in Enterobacteriaceae. APMIS. 115(12): 1400-1408.

Najar, P.S.; Karmostaji, A. and Salmanian, A.H. (2013). Distribution of OXA-type class D β-lactamase genes among nosocomial multi drug resistant Acinetobacter baumannii isolated in Tehran hospitals. Jundishapur Journal of Microbiology. 6(5): 1-5.

Noor, A.M.; Noorain, A.J.; Zaw, Z.H. and Shoon, L.W. (2014). Bacteria identification from microscopic morphology: a survey. International Journal on Soft Computing, Artificial Intelligence and Applications. 3(2).

Papp-Wallace, K.M.; Nguyen, N.Q.; Jacobs, M.R.; Bethel, C.R.; Barnes, M.D.; Kumar, V.; Bajaksouzian, S.; Rudin, S.D.; Rather, P.N.; Bhavsar, S. and Ravikumar, T. (2018). Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. Journal of Medicinal Chemistry. 61(9): 4067-4086.

Pérez-Pérez, F. and Hanson, N.D. (2002). Detection of Plasmid-Mediated AmpC-Lactamase Genes in Clinical Isolates by Using Multiplex PCR. Journal of Clinical Microbiology. 40: 2153-2162.

Polse, R.F.; Yousif, S.Y. and Assafi, M.S. (2016). Prevalence and molecular characterization of extended spectrum β-Lactamases-producing uropathogenic Escherichia coli isolated in Zakho, Iraq. Journal of Microbiology and Infectious Diseases. 6: 163-167.

Saied, T.; Elkholy, A.; Hafez, S.F.; Basim, H.; Wasfy, M.O.; El-Shoubary, W.; Samir, A.; Pimentel, G. and Talaat, M. (2011). Antimicrobial resistance in pathogens causing nosocomial bloodstream infections in university hospitals in Egypt. American Journal of Infection Control. 39(9): 61-65.

Saito, R.; Koyano, S.; Dorin, M.; Higurashi, Y.; Misawa, Y.; Nagano, N.; Kaneko, T. and Moriya, K. (2015). Evaluation of a simple phenotypic method for the detection of carbapenemase-producing Enterobacteriaceae. Journal of Microbiological Methods. 108: 45-48.

Shanthi, M.; Sekar, U.; Kamalanathan, A. and Sekar, B. (2014). Detection of New Delhi metallo β-lactamase-1 (NDM-1) carbapenemase in Pseudomonas aeruginosa in a single centre in southern India. The Indian Journal of Medical Research. 140(4): 546.
Sorour, A.E.; Wali, I.E. and El-Hodaky, S.K. (2008). OXA-Type-β-Lactamases among Extended-Spectrum-Cephalosporin Non-Susceptible Pseudomonas aeruginosa Isolates Collected from a Large Teaching Hospital in Cairo. Egyptian Journal of Medical Microbiology. 17(4): 565-572.

Tamma, P.D.; Goodman, K.E.; Harris, A.D.; Tekle, T.; Roberts, A.; Taiwo, A. and Simner, P.J. (2016). Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clinical Infectious Diseases. 64(3): 257-264.

Trung, N.T.; Tran, T.T.H.; Dao, T.Q.; Mai, T.B.; Phan, Q.H.; Christian, G.M. and Thirumalaisamy, P.V. (2015). Simple multiplex PCR assays to detect common pathogens and associated genes encoding for acquired extended spectrum β-lactamases (ESBL) or carbapenemases from surgical site specimens in Vietnam. Annals of Clinical Microbiology and Antimicrobials. 14: 1-23.

Virginia, M.P.; Patricia, J.S.; David, R.L.; Darcie, E.R.; William, B.B.; April, M.B.; Zabrina, C.L.; Angella, C.K.; Mary, J.F.; Richard, B.T.; Stephen, G.J.; Brandi, M.L. and Sanchita, D. (2017). Modified Carbapenem Inactivation Method for Phenotypic Detection of Carbapenemase Production among Enterobacteriaceae. Journal of Clinical Microbiology. 55: 2321-2333.